FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2743604947> ?p ?o ?g. }

• W2743604947 endingPage "72146" @default.
• W2743604947 startingPage "72133" @default.
• W2743604947 abstract "// Eleonora Di Zanni 1, 4 , Giovanna Bianchi 2 , Roberto Ravazzolo 1, 3 , Lizzia Raffaghello 2 , Isabella Ceccherini 1 and Tiziana Bachetti 1 1 U.O.C. Genetica Medica, Istituto Giannina Gaslini, Genova, Italy 2 Laboratorio di Oncologia, IRCCS G. Gaslini, Genova, Italy 3 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health and CEBR, Università degli Studi di Genova, Genova, Italy 4 Present Address: Istituto di Biofisica, CNR, Genova, Italy Correspondence to: Tiziana Bachetti, email: tiziana.bachetti@tin.it Keywords: PHOX2B, ALK, neuroblastoma, gene expression regulation, drug screening Received: October 25, 2016      Accepted: July 18, 2017      Published: August 04, 2017 ABSTRACT The pathogenic role of the PHOX2B gene in neuroblastoma is indicated by heterozygous mutations in neuroblastoma patients and by gene overexpression in both neuroblastoma cell lines and tumor samples. PHOX2B encodes a transcription factor which is crucial for the correct development and differentiation of sympathetic neurons. PHOX2B overexpression is considered a prognostic marker for neuroblastoma and it is also used by clinicians to monitor minimal residual disease. Furthermore, it has been observed that neuronal differentiation in neuroblastoma is dependent on down-regulation of PHOX2B expression, which confirms that PHOX2B expression may be considered a target in neuroblastoma. Here, PHOX2B promoter or 3′ untranslated region were used as molecular targets in an in vitro high-throughput approach that led to the identification of molecules able to decrease PHOX2B expression at transcriptional and likely even at post-transcriptional levels. Further functional investigations carried out on PHOX2B mRNA levels and biological consequences, such as neuroblastoma cell apoptosis and growth, showed that chloroquine and mycophenolate mofetil are most promising agents for neuroblastoma therapy based on down-regulation of PHOX2B expression. Finally, a strong correlation between the effect of drugs in terms of down-regulation of PHOX2B expression and of biological consequences in neuroblastoma cells confirms the role of PHOX2B as a potential molecular target in neuroblastoma." @default.
• W2743604947 created "2017-08-17" @default.
• W2743604947 creator A5004437953 @default.
• W2743604947 creator A5023392873 @default.
• W2743604947 creator A5024833459 @default.
• W2743604947 creator A5039393891 @default.
• W2743604947 creator A5044191357 @default.
• W2743604947 creator A5073453050 @default.
• W2743604947 date "2017-08-04" @default.
• W2743604947 modified "2023-09-23" @default.
• W2743604947 title "Targeting of<i>PHOX2B</i>expression allows the identification of drugs effective in counteracting neuroblastoma cell growth" @default.
• W2743604947 cites W1499786363 @default.
• W2743604947 cites W1632840752 @default.
• W2743604947 cites W1664626534 @default.
• W2743604947 cites W175146070 @default.
• W2743604947 cites W1964294369 @default.
• W2743604947 cites W1970174011 @default.
• W2743604947 cites W1971050469 @default.
• W2743604947 cites W1991001144 @default.
• W2743604947 cites W1997706272 @default.
• W2743604947 cites W1997985266 @default.
• W2743604947 cites W2008756110 @default.
• W2743604947 cites W2012404242 @default.
• W2743604947 cites W2019946163 @default.
• W2743604947 cites W2025523323 @default.
• W2743604947 cites W2037753888 @default.
• W2743604947 cites W2044380024 @default.
• W2743604947 cites W2051945714 @default.
• W2743604947 cites W2057312647 @default.
• W2743604947 cites W2065657493 @default.
• W2743604947 cites W2078801608 @default.
• W2743604947 cites W2080162017 @default.
• W2743604947 cites W2080531920 @default.
• W2743604947 cites W2090721555 @default.
• W2743604947 cites W2101598041 @default.
• W2743604947 cites W2112106048 @default.
• W2743604947 cites W2118071133 @default.
• W2743604947 cites W2126352399 @default.
• W2743604947 cites W2131731825 @default.
• W2743604947 cites W2141614615 @default.
• W2743604947 cites W2141977652 @default.
• W2743604947 cites W2150700030 @default.
• W2743604947 cites W2152623470 @default.
• W2743604947 cites W2157003997 @default.
• W2743604947 cites W2180351621 @default.
• W2743604947 cites W2184263186 @default.
• W2743604947 cites W2270134702 @default.
• W2743604947 cites W2280307522 @default.
• W2743604947 cites W2286553073 @default.
• W2743604947 cites W2288587365 @default.
• W2743604947 cites W2341775915 @default.
• W2743604947 cites W2589692779 @default.
• W2743604947 cites W4206180447 @default.
• W2743604947 cites W4241040615 @default.
• W2743604947 cites W838598447 @default.
• W2743604947 cites W91313376 @default.
• W2743604947 doi "https://doi.org/10.18632/oncotarget.19922" @default.
• W2743604947 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5641117" @default.
• W2743604947 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29069774" @default.
• W2743604947 hasPublicationYear "2017" @default.
• W2743604947 type Work @default.
• W2743604947 sameAs 2743604947 @default.
• W2743604947 citedByCount "8" @default.
• W2743604947 countsByYear W27436049472018 @default.
• W2743604947 countsByYear W27436049472019 @default.
• W2743604947 countsByYear W27436049472020 @default.
• W2743604947 countsByYear W27436049472021 @default.
• W2743604947 countsByYear W27436049472022 @default.
• W2743604947 crossrefType "journal-article" @default.
• W2743604947 hasAuthorship W2743604947A5004437953 @default.
• W2743604947 hasAuthorship W2743604947A5023392873 @default.
• W2743604947 hasAuthorship W2743604947A5024833459 @default.
• W2743604947 hasAuthorship W2743604947A5039393891 @default.
• W2743604947 hasAuthorship W2743604947A5044191357 @default.
• W2743604947 hasAuthorship W2743604947A5073453050 @default.
• W2743604947 hasBestOaLocation W27436049471 @default.
• W2743604947 hasConcept C104317684 @default.
• W2743604947 hasConcept C150194340 @default.
• W2743604947 hasConcept C204315192 @default.
• W2743604947 hasConcept C2776715637 @default.
• W2743604947 hasConcept C502942594 @default.
• W2743604947 hasConcept C54355233 @default.
• W2743604947 hasConcept C60644358 @default.
• W2743604947 hasConcept C81885089 @default.
• W2743604947 hasConcept C86803240 @default.
• W2743604947 hasConceptScore W2743604947C104317684 @default.
• W2743604947 hasConceptScore W2743604947C150194340 @default.
• W2743604947 hasConceptScore W2743604947C204315192 @default.
• W2743604947 hasConceptScore W2743604947C2776715637 @default.
• W2743604947 hasConceptScore W2743604947C502942594 @default.
• W2743604947 hasConceptScore W2743604947C54355233 @default.
• W2743604947 hasConceptScore W2743604947C60644358 @default.
• W2743604947 hasConceptScore W2743604947C81885089 @default.
• W2743604947 hasConceptScore W2743604947C86803240 @default.
• W2743604947 hasIssue "42" @default.
• W2743604947 hasLocation W27436049471 @default.
• W2743604947 hasLocation W27436049472 @default.
• W2743604947 hasLocation W27436049473 @default.

• next